---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-064145"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T14:35:37.626844+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Phase 1b for GT-02287 enrolls 16 patients; biomarker data now expected Q4 2025

## Summary
- Enrollment reached 16 participants (target 15-20) despite 2-month protocol delay.
- Independent DMC recommends continue study unchanged; no serious adverse events reported.
- Faster enrollment means 90-day visit and CSF biomarker results earlier in Q4 2025 vs. Q1 2026.
- Screening window extended through July 31, 2025; planning to request dosing extension beyond 90 days in Australia.
- Long-term toxicology studies near completion; update on dosing extension expected before end of Q3 2025.

## SEC filing metadata
- accession: 0001104659-25-064145
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465925064145/0001104659-25-064145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465925064145/tm2518735d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-064145
- JSON: https://secwatch.observer/filing/0001104659-25-064145.json
- Plain text: https://secwatch.observer/filing/0001104659-25-064145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.